10-KPeriod: FY2012

Edwards Lifesciences Corp Annual Report, Year Ended Dec 31, 2012

Filed February 28, 2013For Securities:EW

Summary

Edwards Lifesciences Corporation's 2012 10-K filing reveals a strong year of growth, driven primarily by its Transcatheter Heart Valves (THV) segment, which saw sales increase by 65.4%. This growth was significantly boosted by the U.S. launch of the Edwards SAPIEN valve in late 2011. The Surgical Heart Valve Therapy segment showed modest growth of 0.4%, while Critical Care sales remained flat. Overall, net sales grew by 13.2% year-over-year, reaching $1.9 billion. The company's financial health appears robust, with a substantial increase in gross profit margin to 74.0% in 2012, up from 70.8% in 2011. This improvement was attributed to a favorable product mix, particularly higher THV sales, and the positive impact of foreign currency exchange rates. Research and development expenses also increased by 18.3%, reflecting continued investment in product innovation, especially within the THV segment, with new valve systems in development. The company also continued its share repurchase program, demonstrating a commitment to returning value to shareholders.

Financial Highlights

52 data points
Beta

Revenue

$1.90B

74.2% Gross Margin

Net Income

$291.50M

15.3% Net Margin

EPS (Diluted)

$0.41

Total Assets

$2.22B

Cash & Equivalents

$310.90M

Free Cash Flow

$253.10M

Financial Statements
Beta
Revenue$1.90B
Cost of Revenue$491.00M
Gross Profit$1.41B
R&D Expenses$291.30M
SG&A Expenses$697.40M
Interest Expense$4.40M
Net Income$291.50M
EPS (Basic)$0.42
EPS (Diluted)$0.41
Shares Outstanding (Basic)689.40M
Shares Outstanding (Diluted)709.80M

Key Highlights

  • 1Net sales increased by 13.2% to $1.9 billion in 2012, driven by strong performance in Transcatheter Heart Valves (THV).
  • 2Transcatheter Heart Valves (THV) segment sales surged by 65.4% to $552.1 million, largely due to the U.S. launch of the Edwards SAPIEN valve.
  • 3Gross profit margin improved significantly to 74.0% in 2012 from 70.8% in 2011, benefiting from a favorable product mix and foreign currency impacts.
  • 4Research and Development (R&D) spending increased by 18.3% to $291.3 million, highlighting continued investment in innovation, particularly for THV.
  • 5The company maintained a strong balance sheet with total assets of $2.22 billion and healthy liquidity.
  • 6Edwards Lifesciences continued its share repurchase program, repurchasing $350.3 million of common stock in 2012.
  • 7The company operates with a diversified sales base, with 57% of sales generated internationally in 2012.

Frequently Asked Questions

The primary driver of sales growth in 2012 was the Transcatheter Heart Valves (THV) segment, which experienced a 65.4% increase in net sales. This surge was significantly fueled by the U.S. commercial launch of the Edwards SAPIEN transcatheter heart valve in late 2011, expanding its market reach.

Profitability improved in 2012. The gross profit margin increased to 74.0% from 70.8% in 2011. This improvement was attributed to a more favorable product mix, with higher sales from the more profitable Transcatheter Heart Valves segment, and positive impacts from foreign currency exchange rate fluctuations.

Edwards Lifesciences continues to invest heavily in R&D, increasing spending by 18.3% to $291.3 million in 2012. The focus is on developing innovative technologies, particularly within structural heart disease and critical care monitoring. Significant investment is directed towards advancing transcatheter valve technologies, including next-generation valve systems and minimally invasive surgical options.

No, Edwards Lifesciences has never paid cash dividends on its capital stock and currently has no plans to do so. The company's policy is to retain future earnings for reinvestment in the business.